AR036331A1 - Compuestos utiles como intermediarios en la elaboracion de inhibidores de cetp y procedimiento para obtener dichos intermediarios e inhibidores - Google Patents

Compuestos utiles como intermediarios en la elaboracion de inhibidores de cetp y procedimiento para obtener dichos intermediarios e inhibidores

Info

Publication number
AR036331A1
AR036331A1 ARP020101576A ARP020101576A AR036331A1 AR 036331 A1 AR036331 A1 AR 036331A1 AR P020101576 A ARP020101576 A AR P020101576A AR P020101576 A ARP020101576 A AR P020101576A AR 036331 A1 AR036331 A1 AR 036331A1
Authority
AR
Argentina
Prior art keywords
inhibitors
intermediaries
procedure
development
useful compounds
Prior art date
Application number
ARP020101576A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR036331A1 publication Critical patent/AR036331A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

El compuesto es éster etílico del ácido (2R,4S)-2-etil-4-metoxicarbonilamino-6-trifluormetil-3,4-dihidro-2H-quinolina-1-carboxílico de fórmula (1) útil como intermediario para la síntesis de inhibidores de la proteína de transferencia del éster de colesterilo (CETP). También se dan a conocer los procedimientos para obtener dichos intermediarios e inhibidores.
ARP020101576A 2001-04-30 2002-04-29 Compuestos utiles como intermediarios en la elaboracion de inhibidores de cetp y procedimiento para obtener dichos intermediarios e inhibidores AR036331A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28752201P 2001-04-30 2001-04-30

Publications (1)

Publication Number Publication Date
AR036331A1 true AR036331A1 (es) 2004-09-01

Family

ID=23103272

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP020101576A AR036331A1 (es) 2001-04-30 2002-04-29 Compuestos utiles como intermediarios en la elaboracion de inhibidores de cetp y procedimiento para obtener dichos intermediarios e inhibidores
ARP020101575A AR035963A1 (es) 2001-04-30 2002-04-29 Compuestos derivados de trifluormetilbenceno utiles como intermedios de los inhibidores de la proteina de transferencia del ester de colesterilo y procedimientos para su preparacion
ARP040102071A AR044706A2 (es) 2001-04-30 2004-06-15 Procedimientos para preparar 4-aminoquinolinas, inhibidores de cetp

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP020101575A AR035963A1 (es) 2001-04-30 2002-04-29 Compuestos derivados de trifluormetilbenceno utiles como intermedios de los inhibidores de la proteina de transferencia del ester de colesterilo y procedimientos para su preparacion
ARP040102071A AR044706A2 (es) 2001-04-30 2004-06-15 Procedimientos para preparar 4-aminoquinolinas, inhibidores de cetp

Country Status (24)

Country Link
US (3) US6689897B2 (es)
EP (2) EP1425270B1 (es)
JP (2) JP3924250B2 (es)
KR (2) KR100639745B1 (es)
CN (3) CN100357265C (es)
AR (3) AR036331A1 (es)
AT (2) ATE321755T1 (es)
AU (1) AU2002253448B2 (es)
BR (2) BR0209238A (es)
CA (2) CA2445623A1 (es)
CZ (2) CZ20032900A3 (es)
DE (2) DE60209004T2 (es)
DK (2) DK1383734T3 (es)
ES (2) ES2259080T3 (es)
HU (2) HU225777B1 (es)
IL (2) IL157544A0 (es)
MX (2) MXPA03009936A (es)
PL (2) PL366700A1 (es)
PT (1) PT1425270E (es)
RU (2) RU2259355C2 (es)
TW (1) TWI250974B (es)
WO (2) WO2002088069A2 (es)
YU (2) YU84303A (es)
ZA (2) ZA200306599B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US20040002615A1 (en) * 2002-06-28 2004-01-01 Allen David Robert Preparation of chiral amino-nitriles
JP2006021999A (ja) * 2002-07-12 2006-01-26 Kaneka Corp 光学活性β−アミノニトリル化合物およびその対掌体アミド化合物の製造方法
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
MXPA05003456A (es) * 2002-10-04 2005-07-05 Millennium Pharm Inc Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias.
ATE407670T1 (de) 2002-12-20 2008-09-15 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
US7601842B2 (en) 2003-02-18 2009-10-13 Takasago International Corporation Method for producing an optically active tetrahydroquinoline
BRPI0407954A (pt) * 2003-03-17 2006-03-07 Kaneka Corp processo para a produção de derivado de amida de ácido (r)-3-[4-(trifluorometil) fenilamino]-pentanóico
US7223859B2 (en) 2003-03-17 2007-05-29 Pfizer Inc. Method for producing (R)-3-[4-(trifluoromethyl) phenylamino]-pentanoic acid amide derivative
WO2005030185A2 (en) 2003-09-26 2005-04-07 Japan Tobacco Inc. Method of inhibiting remnant lipoprotein production
BRPI0414186A (pt) * 2003-10-08 2006-10-31 Lilly Co Eli compostos, métodos de antagonizar a atividade de cetp, de tratar ou prevenir uma doença, de diminuir o colesterol ldl plasmático em um mamìmero, de tratar e/ou prevenir seqüelas patológicas, formulação farmacêutica, e, uso de um composto
JP4839221B2 (ja) * 2003-11-07 2011-12-21 ジェイ ジェイ ファーマ，インコーポレイテッド Ｈｄｌを高める併用療法用複合物
AR048528A1 (es) * 2004-04-07 2006-05-03 Millennium Pharm Inc Compuestos derivados de quinolina como antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias y composiciones farmacéuticas que los contienen.
CA2570688A1 (en) * 2004-06-24 2006-02-02 Eli Lilly And Company Compounds and methods for treating dyslipidemia
DE102004031656A1 (de) * 2004-06-30 2006-01-19 Merck Patent Gmbh Tetrahydrochinoline
US7700774B2 (en) * 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
AU2006216713A1 (en) 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20100041911A1 (en) * 2005-06-20 2010-02-18 Astrazeneca Ab Process For The Production Of (Alkoxycarbonylamino)alkyl Sulfonates
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
DE102006031149A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006032391A1 (de) * 2006-07-04 2008-01-17 Merck Patent Gmbh Fluortenside
DE102006031143A1 (de) * 2006-07-04 2008-01-24 Merck Patent Gmbh Fluortenside
DE102006031151A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006031262A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
AR065670A1 (es) 2007-03-09 2009-06-24 Indigene Pharmaceuticals Inc Combinacion de metformina r-(+) lipoato y agentes antihiperlipidemicos para el tratamiento de hiperglucemia diabetica y complicaciones diabeticas
JP2011256110A (ja) * 2008-09-30 2011-12-22 Takeda Chem Ind Ltd ヘキサヒドロピロロキノリンの製造法
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
AU2012243583B2 (en) 2011-04-12 2015-10-22 Chong Kun Dang Pharmaceutical Corp. Cycloalkenyl aryl derivatives for CETP inhibitor
PL2729142T3 (pl) * 2011-07-08 2018-10-31 Novartis Ag Sposób leczenia miażdżycy tętnic u osobników z wysokim poziomem triglicerydów
CN105143193B (zh) 2013-01-31 2017-12-15 株式会社钟根堂 作为cetp抑制剂的联芳基或杂环联芳基取代的环己烯衍生化合物
HK1221073A1 (zh) * 2013-11-11 2017-05-19 Lonza Ltd 利用路易斯酸制备第13族元素的氰基化合物的方法
LT3180314T (lt) * 2014-08-12 2022-11-10 Newamsterdam Pharma B.V. Sintetinių tarpinių junginių, skirtų tetrahidrochinolino darinių gamybai, gavimo būdas
CN105294559B (zh) * 2015-06-24 2017-11-14 厦门法茉维特动物药业有限公司 一种医药中间体4‑氨基喹啉类化合物的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW205037B (es) * 1989-10-06 1993-05-01 Takeda Pharm Industry Co Ltd
ES2257864T3 (es) 1998-07-10 2006-08-01 Massachusetts Institute Of Technology Ligandos para metales y procesos mejorados catalizados por metales basados en los mismos.
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines

Also Published As

Publication number Publication date
RU2003131870A (ru) 2005-01-27
YU84403A (sh) 2006-08-17
KR100591998B1 (ko) 2006-06-22
DK1425270T3 (da) 2006-07-03
HU225777B1 (en) 2007-08-28
YU84303A (sh) 2006-05-25
ATE316957T1 (de) 2006-02-15
DK1383734T3 (da) 2006-05-15
US20030216576A1 (en) 2003-11-20
EP1425270B1 (en) 2006-03-29
HUP0304041A2 (hu) 2004-04-28
KR20040015200A (ko) 2004-02-18
AU2002253448B2 (en) 2007-07-05
EP1425270A2 (en) 2004-06-09
JP3924250B2 (ja) 2007-06-06
IL157546A0 (en) 2004-03-28
ATE321755T1 (de) 2006-04-15
WO2002088069A2 (en) 2002-11-07
DE60209004D1 (de) 2006-04-13
WO2002088069A9 (en) 2003-12-04
BR0209291A (pt) 2004-07-13
DE60210265T2 (de) 2006-10-12
WO2002088069A3 (en) 2003-02-20
EP1383734B1 (en) 2006-02-01
CN1529696A (zh) 2004-09-15
CZ20032898A3 (cs) 2004-07-14
US6689897B2 (en) 2004-02-10
RU2003131871A (ru) 2005-04-10
HUP0304041A3 (en) 2005-08-29
JP2004527556A (ja) 2004-09-09
CN1297541C (zh) 2007-01-31
WO2002088085A3 (en) 2004-03-25
EP1383734A2 (en) 2004-01-28
TWI250974B (en) 2006-03-11
IL157544A0 (en) 2004-03-28
PL366584A1 (en) 2005-02-07
ZA200306600B (en) 2004-08-25
US20030073843A1 (en) 2003-04-17
KR20040030603A (ko) 2004-04-09
RU2259355C2 (ru) 2005-08-27
JP2004531541A (ja) 2004-10-14
PT1425270E (pt) 2006-07-31
CA2445693A1 (en) 2002-11-07
HK1062294A1 (en) 2004-10-29
CN1680292A (zh) 2005-10-12
US20020177716A1 (en) 2002-11-28
PL366700A1 (en) 2005-02-07
MXPA03009936A (es) 2004-01-29
HUP0304039A2 (hu) 2004-03-29
ES2256461T3 (es) 2006-07-16
CA2445623A1 (en) 2002-11-07
WO2002088085A2 (en) 2002-11-07
BR0209238A (pt) 2004-06-15
RU2265010C2 (ru) 2005-11-27
AR035963A1 (es) 2004-07-28
CN1267411C (zh) 2006-08-02
DE60209004T2 (de) 2006-09-28
MXPA03009935A (es) 2004-01-29
CZ20032900A3 (cs) 2004-06-16
ES2259080T3 (es) 2006-09-16
JP3924251B2 (ja) 2007-06-06
KR100639745B1 (ko) 2006-10-30
CN1505609A (zh) 2004-06-16
DE60210265D1 (de) 2006-05-18
AR044706A2 (es) 2005-09-21
CN100357265C (zh) 2007-12-26
US6600045B2 (en) 2003-07-29
US6706881B2 (en) 2004-03-16
HUP0304039A3 (en) 2005-10-28
ZA200306599B (en) 2004-10-22

Similar Documents

Publication Publication Date Title
AR036331A1 (es) Compuestos utiles como intermediarios en la elaboracion de inhibidores de cetp y procedimiento para obtener dichos intermediarios e inhibidores
CR8530A (es) Intermediarios de quinolona como inhibidores de receptores de tirosina quinasas y la sintesis de los mismos
EA200100451A1 (ru) Замещенные аналоги бензопирана для лечения воспаления
EA200400815A1 (ru) Контролируемый синтез зипразидона и его композиции
ATE359786T1 (de) Camptothecin derivate
ES2150808T3 (es) Forma cristalina de (4-trifluorometil)-anilida de acido 5-metilisoxazol-4-carboxilico.
ES2021941A6 (es) Procedimiento para la preparacion de nuevos derivados de pirimidinil-piperacinil-alquil azoles.
AR016175A1 (es) Compuestos derivados del acido dihidroxihexanoico, su uso para la preparacion de medicamentos y composiciones de los mismos.
MX9304399A (es) Proceso novedoso para preparar [[2-bromoetil)-amino]metil]-2-nitro-1h-imidazol-1-etanol quiral y compuestos relacionados.
PT775117E (pt) Analogos de 2-nitroimidazole fluorinados para detectar celulas de tumor hipoxicas
ES532147A0 (es) 1h-imidazol-1-etanol y esteres derivados del mismo, asi como procedimiento para su obtencion
ES496038A0 (es) Procedimiento para la obtencion de 2-hidroxialquil-3,4,5- trihidroxi-piperidinas
AR006058A1 (es) Procedimientos para preparar compuestos de dicianoacetato y de 1,2-pirazol-5-amino-3-substituido
CY1111606T1 (el) Διαδικασια διαχωρισμου για to (r)-(-)-2-yδροξy-2- (2-χλωροφαινυλ) οξικο οξυ
EA199900204A1 (ru) Способы и промежуточные соединения для получения замещенных производных хроманола
ES8300711A1 (es) Un procedimiento para la preparacion de un derivado cis-4,5-disustituidos de imidazolidin-2-ona opticamente activo.
BRPI0409154A (pt) processo para a preparação de 5-(haloacetil)-8-(óxi substituìdo)-(1h)-quinolin-2-onas
EA200400806A1 (ru) Способ получения эхинокандиновых соединений
BR9912870A (pt) Processo para sìntese de derivados de (1h) - benzo (c)quinolizina-3-onas
ATE416174T1 (de) Substituierte homopiperidylbenzimidazolanaloga als fundusrelaxantien
BR0110805A (pt) Processo para a preparação de compostos de anilina
ATE9225T1 (de) Derivate des 5-hydroxy-tetrahydro-2-furanons.
PT745081E (pt) Derivados de dissulfureto de inda-2-mercaptoacetilamida uteis como inibidores da encefalinase
BR0010488A (pt) Tienocicloalqu(en)ilamino-1,3,5-triazinas substituìdas
MX9412A (es) Derivados del acido ciclopropano carboxilico, su procedimiento de preparacion y su aplicacion como pesticidas

Legal Events

Date Code Title Description
FB Suspension of granting procedure